Asset

LENIOLISIB PHOSPHATE

Pharming Group N.V. ADS each representing 10 ordinary shares

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02859727phase2_3terminated2016-09-082025-01-30Pharming Technologies B.V.Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

FDA applications (1)

ApplicationTypeApplicant
NDA 217759NDAPHARMING TECHNOLOGIES BV

Marketed products (1)

  • JOENJA